搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
ENDPOINTS NEWS
1 小时
RFK Jr. evades questions on vaccines and autism in written responses to senators
Robert F. Kennedy Jr.’s chances of becoming HHS chief likely hinge on one of his more controversial stances: that vaccines ...
ENDPOINTS NEWS
1 小时
Genentech joins suits against STD clinics it says get 'unlawful' 340B discounts
Genentech sues federal government over 340B discounts to STD clinics, joining Amgen, Eli Lilly and UCB in challenging program eligibility.
ENDPOINTS NEWS
4 小时
After more deliberation, England agrees to pay for Vertex’s gene thera ...
NHS England & Vertex reach deal for sickle cell gene therapy Casgevy, making it available at an undisclosed reduced price ...
ENDPOINTS NEWS
5 小时
AstraZeneca scraps UK vaccine site expansion after government budget cuts
AstraZeneca has canceled its plans to expand its vaccine manufacturing site in Speke, UK, after the new UK government trimmed ...
ENDPOINTS NEWS
5 小时
Daiichi Sankyo taps new CEO, aims to build up ADC franchise
Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1. Okuzawa is currently Daiichi’s chief operating officer.
ENDPOINTS NEWS
8 小时
Celltrion looks to buy US facilities to sidestep potential Trump tariffs
South Korean biopharma contract manufacturer Celltrion is considering acquiring US manufacturing sites to mitigate President ...
ENDPOINTS NEWS
9 小时
AbbVie raises Skyrizi and Rinvoq estimates, predicts $31B in 2027 sales
Rinvoq to $31B amid Humira decline. Skyrizi hit $11.7B and Rinvoq $5.97B in 2024, while Humira fell to $9B from $14.4B in 2023.
ENDPOINTS NEWS
10 小时
Novartis claims best earnings in years, validating shift to pure-play strategy
Novartis said Friday that last year was one of its 'strongest' financial performances in its history following a multiyear ...
ENDPOINTS NEWS
14 小时
Friday IPO doubleheader from Maze and Metsera brings life to biotech debuts
Metsera and Maze Therapeutics priced their Nasdaq IPOs, raising $275M and $140M respectively. Both companies backed by ARCH ...
ENDPOINTS NEWS
1 天
Regeneron wins appeals court order backing halt on Eylea biosimilars
Two biotech companies failed to reverse an order barring them from selling biosimilars of Regeneron’s eye disease drug Eylea ...
ENDPOINTS NEWS
1 天
FDA approves Axsome's acute migraine treatment after 2022 rejection
More than two and a half years after the FDA rejected its migraine treatment, Axsome Therapeutics received an approval for ...
ENDPOINTS NEWS
1 天
Key GOP senator is ‘struggling’ with Kennedy nomination over vaccine an ...
A day after largely fending off criticism of his past controversial comments, HHS nominee Robert F. Kennedy Jr. faced a far ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈